Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It’s 401k suckers Friday buy high sell low so maybe a little green in markets but $44 held well for TMF as I still concur the Fed crew has always been lying about direction. No way to keep rates and markets higher much longer as layoffs from corporations accelerate full force as profits decrease notably Tesla but all other automakers in trouble also..getting nasty out there. Did some
TECS some exiting yesterday on aftermarket spike. Hold 20% now.
RWOD $16 to $30 now + 250% top morning pumper
TPET INDO HNRA HUBC SPCB PRZO Pick your Israel related stock for the quick pump but be ready for the eventual dump…
Israel strikes Iran with a missile, U.S. officials say, as Tehran downplays Netanyahu's apparent retaliation - CBS News
38 minutes ago - Iranians did report hearing the ... explosions were heard in Isfahan and elsewhere in the country, and U.S. officials said Israel had struck Iran with a missile, April 19, 2024....
KA .54 + 12% low floater and decent license agreements such as Genentech
Israel strikes Iran with a missile, U.S. officials say, as Tehran downplays Netanyahu's apparent retaliation - CBS News
38 minutes ago - Iranians did report hearing the ... explosions were heard in Isfahan and elsewhere in the country, and U.S. officials said Israel had struck Iran with a missile, April 19, 2024....
Conflict helps Israeli stocks.. Israel strikes Iran with a missile, U.S. officials say, as Tehran downplays Netanyahu's apparent retaliation - CBS News
38 minutes ago - Iranians did report hearing the ... explosions were heard in Isfahan and elsewhere in the country, and U.S. officials said Israel had struck Iran with a missile, April 19, 2024....
.36 max .. warrant to purchase one ordinary share will be $0.36.
Under the terms of the securities purchase agreement, SuperCom has agreed to sell 8,116,155 ordinary shares (or pre-funded warrants in lieu thereof). In a private placement, which will be consummated concurrently with the offering, SuperCom has also agreed to issue warrants to purchase up to an aggregate of 8,116,155 ordinary shares. The warrants will be immediately exercisable upon issuance, will expire five years from the date of issuance, and will have an exercise price of $0.38 per ordinary share.
Israel strikes Iran with a missile, U.S. officials say, as Tehran downplays Netanyahu's apparent retaliation - CBS News
38 minutes ago - Iranians did report hearing the ... explosions were heard in Isfahan and elsewhere in the country, and U.S. officials said Israel had struck Iran with a missile, April 19, 2024....
Middle East conflict
Nice charting
RWOD ZCMD TPET WLGS HUBC SPCB RELI KA
Redwoods Acquisiti.RWOD
25.91 +250.14% 318.88K
Zhongchao IncZCMD
2.48 +72.22% 1.91M
Redwoods Acquisiti.RWODU
14.00 +46.75% 1.15K
Trio PetroleumTPET
0.449 +38.75% 3.35M
WANG LEE GROUPWLGS
0.72 +37.79% 253.42K
Hub Cyber SecurityHUBC
1.60 +24.03% 2.16M
Supercom LtdSPCB
0.2921 +21.71% 1.21M
Reliance GlobalRELI
0.334 +21.42% 9K
Bio PathBPTH
4.97 +16.67% 231.44K
Kineta IncKA
0.56 +15.20% 8
BPTH not in it anymore but watch levels ..6.44 and 8.14 resistance to look for
AGBA 18m HOLO 2m XPON 4m SECO 1m TOP 5m INMN 9m BNTC 2m MSGM 1m ABVC 9m SNTG 1m TRVN 18m CACO 7m OMH 10m SMFL 2m low floaters on watch
BPTH 6.14 +85-% all out
BPTH $5.83 80% out 6.44 and 8.14 resistance to look for
BPTH 5.78 + 80%
BPTH 4.93 + 50% jump in jump out small floater . Caution###
BPTH 4.59 + 38% small float 700k
BPTH $4 + 25% HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced completion of the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
“We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration (FDA) to review patient study data,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “Enrollment rates have been good, and we look forward to advancing this study in even higher doses with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study with increased levels of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options.”
BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. The current standard of care for patients with AML not eligible for intensive chemotherapy is venetoclax, an oral Bcl-2 inhibitor that targets the BH3 domain of the Bcl-2 protein, in combination with a hypomethylating agent or with low-dose cytarabine. However, many patients become resistant to venetoclax treatment. A published study found that AML patients who had relapsed from frontline venetoclax-based treatment were refractory to salvage therapy and had a median survival of less than 3 months. By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment. Published preclinical Bio-Path studies have shown BP1002 to be a potent inhibitor against the Bcl-2 target, and we believe that its benign safety profile should enable effective BP1002 combination therapy with approved agents, such as decitabine.
The Phase 1/1b clinical trial is being conducted at several leading cancer centers in the United States, including the Weill Medical College of Cornell University, The University of Texas MD Anderson Cancer Center, Scripps Health, and The University of California at Los Angeles Cancer Center. Initially, the dose escalation portion of the clinical plan calls for a total of six evaluable patients to be treated with BP1002 monotherapy over two dose levels in a standard 3+3 design, with a starting dose of 20 mg/m2 and the second dose of 40 mg/m2. The testing of these two dose levels is now complete and the clinical trial will pause for a brief data review by the FDA, and then we expect that dose testing will continue at the next planned higher dose of 60 mg/m2. The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days. The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial. Dr. Roboz is a professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City. Gary Schiller, M.D., The University of California at Los Angeles Cancer Center, Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, and David Hermel, M.D., Scripps Health, are each serving as principal investigators.
New hi 3.85 700k float
BNTC 6.04 had 2m float $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share of $4.80, and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2,584,239 shares of its common stock at a price per pre-funded warrant of $4.7999, to certain institutional accredited investors. The oversubscribed financing was led by Suvretta Capital Management, LLC (“Suvretta Capital”) with participation from new and existing investors including Adage Capital Partners L.P., Nantahala Capital, multiple healthcare-focused funds, and a leading mutual fund. Gross proceeds from the PIPE financing total approximately $40.0 million, before deducting offering expenses. , before deducting offering expenses. The closing price of the Company’s common stock on April 17, 2024 was $4.80
TIRX 1.53 + 217%
THCH 1.43 + 43-% TH International Limited (Nasdaq: THCH), the exclusive operator of Tim Hortons coffee shops and Popeyes restaurants in China (“Tims China” or the “Company”) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023.
FOURTH QUARTER 2023 HIGHLIGHTS
Total revenues reached RMB391.2 million (USD55.1 million), representing a 29.8% increase from the same quarter of 2022.
Net new store openings totaled 149 (34 company owned and operated stores and 109 franchised stores for Tims, and 6 company owned and operated stores for Popeyes).
Adjusted store EBITDA1 was RMB15.9 million (USD2.2 million), representing a 23.9% year-over-year growth.
Adjusted store EBITDA margin2 was 4.6%, approximately unchanged from the same quarter in 2022.
Little monster today
MOB 1.15 news BNTC 7.02 2m float
Mobilicom and Airbus complete successful integration and flight proof-of-concept on Airbus Mid-Sized Jet-UAV for long-range operations
Source: GlobeNewswire Inc.
Mobilicom Limited (Nasdaq: MOB, MOBBW), a provider of cybersecurity and robust solutions for drones and robotics, today announced that in collaboration with Airbus, it has successfully completed the flight proof-of-concept for high-speed jet UAV-to-ground livestreaming of high-definition (HD) video and broadband data. Mobilicom’s cybersecure long-range, high-speed communications systems were successfully integrated into Airbus’ Do-DT25 UAV, one of the top performing target drones in the world.
Mobilicom’s newly released MCU-70 aerial unit was installed on the Airbus jet UAV high-speed long-distance drone, which communicated with Mobilicom’s new MCU-300 ground unit under highly rigorous conditions, including complex high-speed maneuvers at up to 150 meters/second as far as 100 kilometers from the base station. Live, high-speed video has now been made possible by Mobilicom’s MCU-70 aerial unit and can enhance a drone’s performance and accuracy by providing real-time decision support data for human ground crews and digital processing systems.
The Mobilicom MCU-equipped Airbus Target Drones are designed to be used for military training purposes in battle scenarios that simulate various environments with different payloads. Airbus’ Target Systems have been used to train armed forces worldwide in over 3,500 missions.
“We believe that this is an important milestone in Mobilicom’s expansion strategy as we grow our market into mid-sized drones and jet UAVs to serve our growing customer base. We have demonstrated our new systems’ robust capacity to communicate HD video and high-speed data at long range with Airbus, one of the largest aeronautics and space companies in Europe and a worldwide leader,” said Mobilicom CEO and Founder Oren Elkayam. “The proof of concept marks a significant step forward in our end-to-end offering supporting our customers across mini, small and mid-sized platforms, including MESH networking solution for fleet and SWARM operations.”
TIRX HOLO SECO TANH BRSH RETO TRVN
Tian Ruixiang Hold.TIRX
1.30 +168.04% 3.19M
Myndai Inc DRCMYND
5.85 +72.57% 0
MicroCloud Hologra.HOLO
3.28 +46.43% 1.32M
Secoo Holding LtdSECO
0.481 +31.14% 461.66K
Tantech Holdings L.TANH
0.95 +29.25% 208.2K
Bruush Oral Care U.BRSH
0.0551 +24.66% 3.24M
Assure HoldingsIONM
0.76 +20.63% 0
ReTo Eco-SolutionsRETO
1.13 +18.95% 0.24K
Cns PharmaCNSP
0.24 +17.60% 0.05K
Trevena IncTRVN
0.4681 +17.55% 165.16K
TIRX still up nicely 170%.
Tian Ruixiang Hold.TIRX
BSGM 8m CXAI 13m EZGO 3m AWIN 400k LGVN 2m IZM 6m DXYZ PLCE 5m INVO 3m INTZ 1m the low floaters club
EDBL $10.84 + 137% new 200k float pumped to $12.47
INVO 2.94 resistance at play then 3.07- 3.30
PALI 6.98 + 18%
GDXU the trade now $37.43 + 7%
PLCE $11.23
PLCE $8s to 10.63 + 50%
CISS 2.10 so merger with AGFY at .45 ok..
AGFY EDBL IMCC
CISS 1.97 found a bottom finally post reverse split
PLCE children and PROK kidneys been going nicely also
AUVI .80 3m float WISA 8.53
WISA back above $7
INVO VNDA CXAI SPEC PXMD IZM NUTX